FDA Updates Its Criteria For Medicare Coverage Of Device Trials
This article was originally published in The Gray Sheet
Executive Summary
The agency has long been partnering with CMS to set coverage for investigational device exemption studies by designating IDE trials as "category A" or "category B." A new FDA draft guidance and memorandum of understanding between FDA and CMS are intended to modernize the criteria for those trial categories.
You may also be interested in...
FDA Updates IDE Guidance Addressing Medicare Coverage
CMS may have an easier time determining when it should pay for an investigational device as FDA revamps its IDE device-classification scheme.
FDA Abandons Proposal For Interactive, “Pre-Decisional” IDE
The agency finalized a guidance document on investigational device exemption review decisions, dropping a proposal to establish a new, interactive “pre-decisional” IDE process. Industry had been skeptical that the proposed program would improve efficiency of study reviews, and worries that it would require a lot of FDA resources.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.